AstraZeneca entrusts Pfizer with OTC Nexium
This article was originally published in Scrip
Executive Summary
Pfizer has entered an agreement for global over-the-counter (OTC) rights to Nexium (esomeprazole magnesium), AstraZeneca's blockbuster proton pump inhibitor (PPI) for heartburn and related conditions. The patents covering the prescription form of Nexium will start to expire in 2014.